In the past week, HRTX stock has gone down by -4.24%, with a monthly gain of 47.66% and a quarterly plunge of -16.40%. The volatility ratio for the week is 7.81%, and the volatility levels for the last 30 days are 9.84% for Heron Therapeutics Inc The simple moving average for the last 20 days is 3.88% for HRTX stock, with a simple moving average of -34.38% for the last 200 days.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
The 36-month beta value for HRTX is also noteworthy at 1.63. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HRTX is 151.02M, and at present, short sellers hold a 19.85% of that float. The average trading volume of HRTX on December 26, 2024 was 3.15M shares.
HRTX) stock’s latest price update
The stock price of Heron Therapeutics Inc (NASDAQ: HRTX) has plunged by -1.25 when compared to previous closing price of 1.60, but the company has seen a -4.24% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-23 that SAN DIEGO, Dec. 23, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, announced today the relocation of the Company’s headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron’s Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park (“RTP”), one of the most prominent high-tech research and development parks in the United States.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the current year.
HRTX Trading at 1.19% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.80% of loss for the given period.
Volatility was left at 9.84%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares surge +38.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.73% lower at present.
During the last 5 trading sessions, HRTX fell by -4.24%, which changed the moving average for the period of 200-days by -34.44% in comparison to the 20-day moving average, which settled at $1.5210. In addition, Heron Therapeutics Inc saw -7.06% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.18 for the present operating margin
- 0.68 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.19. The total capital return value is set at -0.19.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.3 points at debt to capital in total, while cash flow to debt ratio is standing at -0.05. The debt to equity ratio resting at -4.36. The interest coverage ratio of the stock is -11.96.
Currently, EBITDA for the company is -103.79 million with net debt to EBITDA at -6.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.67. The receivables turnover for the company is 2.2for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.28.
Conclusion
In summary, Heron Therapeutics Inc (HRTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
